Create a Free Profile
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
A blood test that looks for traces of cancer DNA, so your care team may see a change months before a scan does. Find the practices using it and choose the ones you like.
Free to join. No card required.
Tumors shed small pieces of DNA into the bloodstream, known as circulating tumor DNA or ctDNA. A liquid biopsy measures it from an ordinary blood draw. It can show whether traces of cancer remain after treatment, and whether a new mutation has appeared that could make a current medicine stop working.
Interception means acting on that signal: changing or adding treatment when the blood test shows the cancer changing, instead of waiting for it to grow large enough to see on a scan. Some of these strategies have shown promise in trials and are still being studied.
Only your physician can say whether it is right for you.
Before You Match
Several liquid biopsy tests are used in care today. Switching treatment early based on them is mostly happening in trials.
A positive or negative result is one piece of information. Your care team reads it alongside scans and exams.
Insurance coverage depends on the test, the cancer and the reason it is ordered. Ask before testing.
Monitoring usually means a blood draw every few weeks or months. Ask how often, and what would change if a result does.
Health e Match summarized this information from the sources listed below. It is general information, not medical advice.
Liquid biopsy is used in people with solid tumors such as colorectal, breast, lung and bladder cancer. Some tests help choose a targeted treatment at diagnosis; others, called minimal residual disease (MRD) tests, look for traces of cancer after surgery or during treatment.
Many MRD tests are tumor-informed, which means they need a sample of your tumor to build a test personalized to your cancer. Studies of interception, changing treatment based on rising ctDNA, have their own criteria.
The test itself is an ordinary blood draw. For a tumor-informed test, the lab first sequences your tumor sample, so the first result can take a couple of weeks; later tests return faster.
Testing is usually repeated every few weeks to few months, depending on your cancer and treatment plan.
There is no recovery from a blood draw. The follow-up is the plan for results: your oncologist reviews each one, and a positive result may lead to earlier scans. In interception trials, a rising result can trigger a change in treatment as part of the study.
The physical risk is minimal. The real risks are in the results: tests can miss small amounts of cancer or, less often, suggest cancer that is not there, and waiting for results can add anxiety.
Outside of trials, changing treatment based on ctDNA alone has not yet been shown to improve survival for many cancers, so results are read alongside scans and exams.
Coverage depends on the test, the cancer and why it is ordered. Medicare covers some MRD tests for certain cancers; private insurance varies. Many labs offer financial assistance, so ask the practice or the lab before testing.
Questions worth asking in your first conversation:
Standard follow-up uses imaging such as CT or PET scans, blood tumor markers where they apply, and tissue biopsy when something new is found. Liquid biopsy is usually added to these, not used instead of them.
Searching for liquid biopsy interception usually means a long list of names and no way to tell who actually offers it. Here, you meet verified practices that treat what you listed, and you decide who to talk to.
Tell us about you: what you’re living with, what you’ve tried and what you’re exploring.
We only introduce verified practices that treat what you listed.
Swipe on the ones you like. When they swipe back — it’s a match!
Free to join. No card required.
Questions
Some liquid biopsy tests are FDA-approved to help choose a treatment, and others are offered by certified labs. Using rising ctDNA to change treatment before scans show progression is still being studied.
Not today. It is used alongside imaging, not instead of it.
Minimal residual disease testing looks for traces of cancer DNA after treatment, when nothing is visible on a scan, to estimate whether cancer remains.
Your diagnosis, the treatment you are on or have finished, and that you are exploring liquid biopsy monitoring.
Build a free profile in minutes. List what you’re living with and that you’re exploring liquid biopsy interception, and meet the practices that treat it.
Free to join. No card required.
This page is general information, not medical advice, and it was last updated October 15, 2026. healthematch.com makes introductions between patients and practices in the United States. It does not provide medical care, does not enroll anyone in clinical research, and does not recommend any particular procedure or provider. Where a practice has documented a therapy’s regulatory status, it is shown exactly as documented. Are you a practice? See the liquid biopsy interception page for practices.